The grades of four Pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
This week, Repros Therapeutics (NASDAQ:RPRX) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. Shares of the stock have been changing hands at an unusually rapid pace, up 2213.9% from the week prior. For more information, get Portfolio Grader’s complete analysis of RPRX stock.
Johnson & Johnson’s (NYSE:JNJ) ratings are looking better this week, moving up to an A from last week’s B. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. Shares of JNJ have increased 6.2% over the past month, better than the 3.6% increase the S&P 500 has seen over the same period of time. The stock’s dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of JNJ stock.
Bristol-Myers Squibb (NYSE:BMY) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. Wall Street has pushed the stock higher by 10% over the past month. For more information, get Portfolio Grader’s complete analysis of BMY stock.
Watson Pharmaceuticals (NYSE:WPI) shows solid improvement this week. The company’s rating rises from a B to an A. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
